The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and Total Knee Arthroplasty
Figure 1
Pooled incidence of major plus clinically relevant non-major bleeding for RECORD trials 1–4. Patients taking rivaroxaban had more events than patients taking enoxaparin (). In subgroup analysis, more events occurred in patients taking rivaroxaban less than 65 years of age (), weighing less than 90 kg (), and with creatinine clearance over 80 mL/min () [30].
